Allstate Corp Biomarin Pharmaceutical Inc Transaction History

Allstate Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $12,544 - $16,837	155 Added 2.66%	5,978 $618,000
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $305,505 - $371,196	-4,274 Reduced 42.33%	5,823 $483,000
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $750,005 - $935,890	10,097 New	10,097 $778,000
Q3 2020 Nov 13, 2020	SELL	$71.87 - $131.03 $448,828 - $818,282	-6,245 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$79.55 - $124.22 $157,668 - $246,204	1,982 Added 46.49%	6,245 $770,000
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $304,250 - $412,871	4,263 New	4,263 $360,000
Q4 2019 Feb 14, 2020	SELL	$64.27 - $86.37 $2.09 Million - $2.81 Million	-32,536 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $318,599 - $402,314	4,727 Added 17.0%	32,536 $2.19 Million
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $2.23 Million - $2.61 Million	27,809 New	27,809 $2.38 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Allstate Corp, based on Form 13F filings with the SEC.

Stay updated on Allstate Corp with notifications on news.